US Revives Lawsuit Against Pfizer, AstraZeneca Over Iraq Terror Funding
The US court plaintiffs contend that the terrorist group Jaysh al-Mahdi controlled Iraq's health ministry and that 21 defendant medical companies, including AstraZeneca and Pfizer, made corrupt payments to obtain medical-supply contracts.
A US appeals court on Tuesday revived a lawsuit against AstraZeneca, Pfizer and other companies over allegations their contracts with Iraq's health ministry helped fund terrorism that killed Americans during the war in Iraq.
The plaintiffs contend that the terrorist group Jaysh al-Mahdi, sponsored by Hezbollah, controlled Iraq's health ministry and that the 21 defendant US and European medical supply and manufacturing companies made corrupt payments to obtain medical-supply contracts.
The companies have denied any wrongdoing. Representatives from the five corporate groups - AstraZeneca, GE Healthcare USA Holding, Johnson & Johnson Pfizer and Hoffmann-La Roche Inc did not immediately respond to requests for comment.
The lawsuit revived by the US Court of Appeals for the District of Columbia Circuit was brought by family members of victims of attacks in Iraq by the Mahdi group. A federal trial judge dismissed the lawsuit in 2020.
Lawyer Kannon Shanmugam, who argued the appeal on behalf of the companies, did not immediately comment.
The lawyer for the family members, Joshua Branson, also did not immediately comment.
Lawyers for the companies told the appeals court that they provided the Iraqi government "life-saving breast cancer treatments, hemophilia injections, ultrasounds, electrocardiogram machines, and other medical goods" after the US-led invasion of Iraq toppled strongman president Saddam Hussein in 2003.
Shanmugam said in court in September that a ruling against the companies "would have a severe chilling effect on the willingness of companies and non-governmental organizations to conduct essential activities, often at the government's request, in troubled regions."
The plaintiffs contend that the terrorist group Jaysh al-Mahdi, sponsored by Hezbollah, controlled Iraq's health ministry and that the 21 defendant US and European medical supply and manufacturing companies made corrupt payments to obtain medical-supply contracts.
The companies have denied any wrongdoing. Representatives from the five corporate groups - AstraZeneca, GE Healthcare USA Holding, Johnson & Johnson Pfizer and Hoffmann-La Roche Inc did not immediately respond to requests for comment.
The lawsuit revived by the US Court of Appeals for the District of Columbia Circuit was brought by family members of victims of attacks in Iraq by the Mahdi group. A federal trial judge dismissed the lawsuit in 2020.
Lawyer Kannon Shanmugam, who argued the appeal on behalf of the companies, did not immediately comment.
The lawyer for the family members, Joshua Branson, also did not immediately comment.
Lawyers for the companies told the appeals court that they provided the Iraqi government "life-saving breast cancer treatments, hemophilia injections, ultrasounds, electrocardiogram machines, and other medical goods" after the US-led invasion of Iraq toppled strongman president Saddam Hussein in 2003.
Shanmugam said in court in September that a ruling against the companies "would have a severe chilling effect on the willingness of companies and non-governmental organizations to conduct essential activities, often at the government's request, in troubled regions."
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
